Vanda Gains FDA Review for Psoriasis Drug Imsidolimab

FDA Accepts Imsidolimab Application, Sets December 12 Decision Date

Vanda Pharmaceuticals (Nasdaq: VNDA) confirmed on February 25, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for review. The application covers imsidolimab, an investigational treatment for Generalized Pustular Psoriasis (GPP). With the filing accepted, the FDA has established a target action date of December 12, 2026, to complete its review and make a decision on the drug's approval.

Regulatory Milestone Boosts Vanda's Commercial Outlook

The FDA's acceptance of the BLA is a critical step forward for Vanda, moving the company closer to potentially commercializing a new therapy. This regulatory validation signals that the application is sufficiently complete for a substantive review, reducing a key uncertainty for investors. GPP is a rare, chronic, and potentially life-threatening autoinflammatory skin condition, and a successful approval for imsidolimab would open a new, specialized market for Vanda, potentially generating a significant new revenue stream.